Feb. 20 at 6:05 PM
$PPCBD Propanc Biopharma is developing a groundbreaking cancer treatment known as PRP, a pancreatic proenzyme formulation aimed at preventing tumor recurrence and metastasis.
In preclinical studies, PRP has demonstrated several promising and remarkable effects:
Findings suggest that PRP could be an exceptionally promising therapy for cancer treatment. The company has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer, indicating recognition of its potential in addressing unmet medical needs.
For a more detailed overview of Propanc Biopharma's advancements in cancer treatment, you might find the following video informative:
https://www.youtube.com/watch?v=uP-e0h7QXRg&t=532s
